Clinical Trials Directory

Trials / Completed

CompletedNCT00063323

Maintenance Treatment for Abstinent Smokers

Maintenance Treatment for Prevention of Smoking Relapse

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
589 (actual)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
21 Years – 75 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the efficacy and cost-effectiveness of long-term pharmacotherapy (using Zyban and/or nicotine replacement) for reducing the relapse rate associated with stopping smoking.

Detailed description

The goal of this study was to assess relapse prevention outcomes among individuals able to stop smoking when pharmacotherapy is extended beyond the standard duration of treatment. We hypothesized that maintenance treatment with prolonged bupropion use and/or "as needed" use of nicotine gum will reduce relapse to smoking. Participants were recruited through advertisements on radio, television, newspapers, the Internet, and various community outlets. Respondents were pre-screened by telephone using a standard interview. The first participant entered the OLT phase in February 2001; the final NTFU visit took place in October 2005. The study was multi-phased consisting of: 1) eight-week open-label treatment (OLT) with bupropion and nicotine patch; 2) randomized double-blind assignment of OLT successes to 16 weeks of placebo-controlled maintenance treatment (MT); and 3) 24 weeks of non-treatment follow-up (NTFU). Participants received $25 compensation for completing the NTFU visits at Weeks 36 and 48. The Institutional Review Board of the New York State Psychiatric Institute approved the study. The study was performed at the Columbia University Medical Center Smoking Cessation Clinic in New York City.

Conditions

Interventions

TypeNameDescription
DRUGBupropion

Timeline

Start date
2000-08-01
Primary completion
2006-07-01
Completion
2006-07-01
First posted
2003-07-01
Last updated
2017-01-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00063323. Inclusion in this directory is not an endorsement.